title: The impact of TNF superfamily molecules on overall survival in acute myeloid leukaemia: correlation with biological and clinical features.
abstract: B cell-activating factor (BAFF), a proliferation-inducing ligand (APRIL) and apoptosis-inducing ligand (TRAIL) were demonstrated in several haematological diseases including acute myeloid leukemia (AML). Those cytokines are capable of activating a broad spectrum of intracellular signalling cascades that can either induce apoptosis or protect from programmed cell death. We have analysed BAFF, APRIL and TRAIL serum concentrations in 76 patients with newly diagnosed AML and 40 healthy volunteers. The values were significantly higher for APRIL and BAFF but lower for TRAIL compared to healthy volunteers. Induction therapy significantly reduced the values for BAFF and increased them for TRAIL. Moreover, the concentration of BAFF and APRIL was significantly lower and the concentration of TRAIL higher in a group of patients with complete remission compared to non-respondent AML patients. In addition, higher concentrations of BAFF and lower of TRAIL predicted a shorter overall survival, suggesting thereby an important prognostic marker and possible therapeutic target in AML.
authors.affiliation: Department of Haematology, Medical University of Bialystok, 24a Sklodowskiej-Curie, Bialystok, 15-276, Poland, lbolkun@gmail.com.
authors.forename: L
authors.initials: L
authors.lastname: Bolkun
authors.forename: D
authors.initials: D
authors.lastname: Lemancewicz
authors.forename: E
authors.initials: E
authors.lastname: Jablonska
authors.forename: A
authors.initials: A
authors.lastname: Szumowska
authors.forename: U
authors.initials: U
authors.lastname: Bolkun-Skornicka
authors.forename: W
authors.initials: W
authors.lastname: Ratajczak-Wrona
authors.forename: J
authors.initials: J
authors.lastname: Dzieciol
authors.forename: J
authors.initials: J
authors.lastname: Kloczko
mesh_terms: D000293:Adolescent; D000328:Adult; D053264:B-Cell Activating Factor / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood* / Q000175:diagnosis / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate / Q000639:trends; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000097:blood*; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13 / Q000097:blood; D048069:Tumor Necrosis Factors / Q000097:blood; D055815:Young Adult
chemical_list: D053264:B-Cell Activating Factor; D015415:Biomarkers; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; C505719:TNFSF13B protein, human; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13; D048069:Tumor Necrosis Factors
references.citation: Cell Death Dis. 2013 Mar 14;4:e536
references.pmid: 23492767
references.citation: J Exp Med. 2000 Nov 20;192(10):1453-66
references.pmid: 11085747
references.citation: Blood. 2000 Dec 1;96(12):3900-6
references.pmid: 11090076
references.citation: Haematologica. 2005 May;90(5):612-24
references.pmid: 15921376
references.citation: Cytokine. 2013 Mar;61(3):885-91
references.pmid: 23357299
references.citation: Blood. 2003 May 1;101(9):3658-67
references.pmid: 12506034
references.citation: J Clin Oncol. 2003 Dec 15;21(24):4642-9
references.pmid: 14673054
references.citation: Leukemia. 2005 Dec;19(12):2195-202
references.pmid: 16224489
references.citation: Ann Hematol. 2005 Oct;84(11):728-33
references.pmid: 16007425
references.citation: Cytokine. 2003 Dec 21;24(6):244-53
references.pmid: 14609566
references.citation: Immunity. 2004 Dec;21(6):877-89
references.pmid: 15589175
references.citation: Blood. 1992 Oct 1;80(7):1798-803
references.pmid: 1382704
references.citation: Immunol Lett. 2008 Feb 15;116(1):1-6
references.pmid: 18155301
references.citation: Br J Haematol. 1992 Aug;81(4):530-2
references.pmid: 1327064
references.citation: Cytokine Growth Factor Rev. 2013 Jun;24(3):203-15
references.pmid: 23684423
references.citation: Cancer Res. 2004 Feb 1;64(3):1037-43
references.pmid: 14871835
references.citation: Blood. 2000 Jun 15;95(12):3716-24
references.pmid: 10845902
references.citation: Leuk Res. 2011 Jun;35(6):741-9
references.pmid: 21281967
references.citation: Eur J Haematol. 2008 Sep;81(3):177-84
references.pmid: 18510703
references.citation: Blood. 2001 Oct 1;98(7):2183-92
references.pmid: 11568006
references.citation: Exp Mol Pathol. 2009 Aug;87(1):54-8
references.pmid: 19393234
references.citation: J Immunol. 2005 Jul 15;175(2):1232-8
references.pmid: 16002727
references.citation: J Clin Oncol. 2012 Jul 10;30(20):2441-8
references.pmid: 22508825
references.citation: Blood. 2012 Jan 19;119(3):651-65
references.pmid: 22053109
references.citation: Blood. 2010 Jan 21;115(3):453-74
references.pmid: 19880497
references.citation: Annu Rev Immunol. 2003;21:713-58
references.pmid: 12500979
references.citation: J Immunol. 2002 Jun 15;168(12):5993-6
references.pmid: 12055205
references.citation: Mol Cell Biol. 2000 Apr;20(8):2687-95
references.pmid: 10733571
references.citation: Blood. 2002 Oct 1;100(7):2421-9
references.pmid: 12239152
references.citation: Curr Drug Metab. 2007 May;8(4):395-403
references.pmid: 17504227
references.citation: Vitam Horm. 2004;67:257-74
references.pmid: 15110181
references.citation: Nat Immunol. 2002 Mar;3(3):221-7
references.pmid: 11875461
references.citation: Haematologica. 2008 Dec;93(12):1899-902
references.pmid: 18838478
references.citation: Br J Haematol. 2003 Jun;121(5):713-20
references.pmid: 12780785
references.citation: Blood. 2004 Jan 15;103(2):517-22
references.pmid: 12969966
references.citation: Leukemia. 2003 Feb;17(2):379-89
references.pmid: 12592338
references.citation: Am J Hematol. 2012 Jan;87(1):89-99
references.pmid: 22180162
references.citation: Acta Haematol. 2008;120(1):19-30
references.pmid: 18716397
references.citation: Blood. 2009 Jul 30;114(5):937-51
references.pmid: 19357394
references.citation: Blood. 2001 Oct 15;98(8):2301-7
references.pmid: 11588023
references.citation: Mol Immunol. 2005 May;42(7):763-72
references.pmid: 15829264